AgelessRx Review: The Only Seller Here That Ran Its Own Trial, and What It Found

What PEARL actually found

The published abstract is worth reading in the order the authors wrote it.

Design: participants received placebo, 5 mg or 10 mg compounded rapamycin weekly for 48 weeks. "The primary outcome measure was visceral adiposity (by DXA scan), secondary outcomes were blood biomarkers, and lean tissue and bone mineral content."

Results: "Adverse and serious adverse events were similar across all groups. Visceral adiposity did not change significantly (ηp2 = 0.001, p = 0.942), and changes in blood biomarkers remained within normal ranges. Lean tissue mass (ηp2 = 0.202, p = 0.013) and self-reported pain (ηp2 = 0.168, p = 0.015) improved significantly for women using 10 mg rapamycin. Self-reported emotional well-being (ηp2 = 0.108, p = 0.023) and general health (ηp2 = 0.166, p = 0.004) also improved for those using 5 mg rapamycin. No other significant effects were observed." ¹

And the conclusion the authors reached: low-dose intermittent rapamycin "is relatively safe in healthy, normative-aging adults," with future work aiming "to more comprehensively establish efficacy."

That is a safety finding with four positive secondary signals — three of them self-reported, all of them sex- or dose-stratified — and a null on the one endpoint the trial was designed around. It is a real and useful result. It is not a demonstration that rapamycin reverses aging, and the paper does not say it is.

AgelessRx's rapamycin page reports PEARL accurately in its FAQ: "The trial's primary measure–visceral fat–didn't show a significant change, but meaningful secondary findings did." Credit where it is due; that sentence is correct.

The number above it

Scroll up from that FAQ and there is a much bigger number, in much larger type, with a much shorter footnote.

"Our users were 9 biological years younger on average in 1 year." Then, as a display statistic: "Average biological age reduction after 1 year — 9.43 years." And the footnote: "Actual results may vary. Data was self-reported by 300 surveyed Rapamycin customers who checked in with their provider on between 11/1/24-10/1/25."

Three hundred customers. Self-reported. Surveyed. No placebo arm, no blinding, no randomisation, and — by construction — only people still taking the product a year later. Every design feature PEARL was built to eliminate is present here, and this is the figure a visitor meets first.

The two claims are not comparable and the page does not distinguish them. A reader who takes away one number from that page takes away 9.43, not p = 0.942.

There is a second, sharper wrinkle. AgelessRx's own bioavailability study found that compounded rapamycin reaches roughly 31% of the blood level of the same milligram dose of commercial rapamycin, across 44 commercial and 23 compounded users. ³ The product AgelessRx sells at $65 a month is the compounded one; the study concludes that "individualized dosing and routine monitoring of blood rapamycin levels should be utilized." That is a genuinely valuable finding, the company published it, and the rapamycin page cites it. It also means the milligram figure on a compounded label is not the milligram figure in a paper — a distinction that matters far more than a biological-age survey and gets a fraction of the space.

Sermorelin, and the citation that names a different molecule

The sermorelin page's headline sentence is unhedged: "Sermorelin has shown to boost energy, lean muscle mass, and strength by encouraging your body to replenish its own growth hormone safely and gradually, without the risks and side effects of synthetic HGH therapy."

"Has shown to" is a claim of demonstrated effect. So look for the demonstration.

On August 9, 2026, a ClinicalTrials.gov v2 query for AREA[InterventionName]sermorelin returned 11 studies. Not one names sermorelin as an intervention. Every record is generic "growth hormone releasing hormone," or tesamorelin — the synthetic GHRH(1-44) analogue marketed as Egrifta — or a GHRH-plus-arginine diagnostic challenge used to test whether a pituitary responds. Broadening to an intervention search for "sermorelin" returns 27 studies and a free-text search returns 42, with the same outcome: zero registered studies whose intervention is sermorelin. ⁷ If you want the separate and genuinely stronger evidence base for the GHRH analogue that has been trialled, that is a different molecule with a different story — see tesamorelin.

PubMed the same day: sermorelin AND randomized controlled trial[pt] returns 19 records, the most recent published in August 2005. They measure GH response to a bolus, growth in children with GH deficiency, the interaction of somatostatin and GHRH, low-dose dose-response. Energy, lean muscle mass and strength in healthy adults appear in none of them.

Now the part that only this company makes visible. AgelessRx lists five citations under the sermorelin page, and describes the only randomised one in its own words: "This single-blind, randomized, placebo-controlled trial uses Nle²⁷-GRF(1-29), a modified version of Sermorelin that may have increased stability and potency, in 19 men and women aged 55-71 to show improved quality of life."

A modified version. Nineteen people. Single-blind. 1997. The company's own footnote concedes that its strongest primary evidence is for a molecule that is not the one in the vial — which is more than most sellers disclose, and is also exactly the gap between "has shown to boost strength" and what has been shown.

The NAD+ trials that are not about the NAD+ product

The NAD+ injection page promises to "[b]oost energy, improve focus, and support cellular health," with a badge reading "89% saw results by 2nd check-in."

As of August 9, 2026, a PubMed search for "nicotinamide adenine dinucleotide"[tiab] AND (subcutaneous[tiab] OR injection[tiab]) AND randomized controlled trial[pt] returns zero records. ⁸ On ClinicalTrials.gov, an intervention-name query for nicotinamide adenine dinucleotide returns 21 studies; adding a subcutaneous filter to the intervention description returns none. The 21 are oral precursors, IV infusions, NADH supplements and injectable coenzyme I in oncology and cardiology.

Two of those 21 are AgelessRx's own, and this is where reading the registry rather than the molecule name earns its keep. NCT04604704 — phase 2, completed, 36 participants — states that "NAD+ will be applied using iontophoresis patches," in combination with low-dose naltrexone, for fatigue in post-COVID-19 syndrome. NCT07475546 — phase 3, active not recruiting — states that "NAD+ will be taken as a nasal spray of 30mg/day," as one of eight simultaneous interventions including rapamycin, metformin, naltrexone, B12, a proprietary supplement, meditation and exercise. ⁹

So AgelessRx has run NAD+ trials. Neither tested the injection it sells, neither tested it alone, and neither measured energy or focus in healthy adults as a primary outcome. The eleven citations on the injection page tell the same story from the other side: reviews of NAD+ biology, studies of oral precursors, an IV study in people with addictive behaviours, and papers establishing that NAD+ declines with age. All about the molecule. None about the route.

"89% saw results by 2nd check-in" has no denominator, no definition of "results" and no comparator. A company that can write a conflict-of-interest statement and report a null primary endpoint knows what that sentence is worth.

The copper cream, and the one trial nobody cites

The GHK-Cu cream is the most carefully worded product on the site: "Support firmer, smoother-looking skin… Helps soften the look of fine lines… Supports firmer, more resilient-looking skin." Appearance language throughout, and a page that says plainly "GHK-Cu is not FDA-approved to treat medical conditions."

That care is real, and it still lands on the one endpoint that has been tested and did not move.

In 2006, patients undergoing CO2 laser skin resurfacing were randomised to a post-treatment regimen with or without GHK-Cu skincare, assessed by blinded evaluators and computer analysis of erythema, with a validated questionnaire at twelve weeks. Thirteen completed. The conclusion, verbatim: "Objective evaluation found no significant improvement in wrinkles or overall skin quality. However, patient satisfaction was significantly higher for those who used GHK-Cu skin care products." ¹⁰

Thirteen patients is small and a null at that size is weak evidence rather than disproof. It is also, still, the only randomised evidence topical GHK-Cu has for skin appearance. The registry adds nothing yet: the only registered study whose intervention is actually GHK-Cu is NCT07437586, a phase 2 split-wound trial of a 0.1% gel on punch-biopsy wounds, sponsored by Hudson Biotech, still recruiting, no results. ¹¹ AgelessRx lists seven citations for this product. All seven are reviews. The trial is not among them.

Who fills it, and the sentence that goes too far

For everything AgelessRx compounds, the pharmacy is a category rather than a name. "[O]ne of our US-licensed, LegitScript-certified pharmacy partners." "US-based licensed pharmacies that are 503A compounding pharmacies." The terms define "the Pharmacies" as a capitalised party and never say who they are. The only named supplier on the whole site is an ingredient vendor — low-dose naltrexone materials "supplied by the Professional Compounding Centers of America (PCCA)."

The exception proves the rule. For Wegovy, AgelessRx names the filler outright: "NovoCare or Amazon Pharmacy will fulfill all Wegovy® prescriptions," and "AgelessRx only charges for prescription access for Wegovy® and ongoing health monitoring." The one product it does not compound is the one whose chain a reader can follow end to end.

Two FAQ answers also disagree with each other. One: "Every pharmacy we work with is 503A certified." The next: "Every pharmacy we work with is a licensed 503A or 503B compounding pharmacy." 503A and 503B are different statutory regimes with different oversight — and "503A certified" is not a status anyone issues, because 503A is a section of the FD&C Act rather than a certificate.

And then the sentence that goes furthest: "All medications offered on our platform are subject to the same FDA audit and quality controls as any pharmacy medication in the US," followed by "[o]ur products are evaluated by the same standards and approval processes that allow these and other medications to be sold at national pharmacies like Walgreens and CVS."

That is not true of a compounded preparation, and AgelessRx knows it is not true, because the disclaimer at the foot of every product page states the opposite in the correct words: "The FDA has not reviewed or approved compounded products for any use for safety, efficacy, or quality." Both sentences are published. They cannot both be right.

What a good company looks like when the marketing wins

There is no scandal here. AgelessRx has no FDA warning letter — the live index returned nothing for "agelessrx" or "ageless rx" on August 9, 2026, under a query shape verified by a control that does return one. The compounding disclaimer is on every page. The prices are published. The intake is a real per-product clinical triage, not a lead form. And the company has done the single hardest, most expensive, least commercially convenient thing available to it: it ran a randomised trial and published a null primary endpoint.

The failure mode is narrower and more ordinary than fraud. It is that the same organisation which insists on a conflict-of-interest statement will also put a customer survey in 60-point type; that a research team capable of measuring compounded rapamycin's bioavailability will let a page say sermorelin "has shown to boost strength"; that a company running NAD+ trials by patch and by nasal spray will sell an NAD+ injection for focus.

Which makes AgelessRx unusually easy to hold to account, and unusually worth holding. Every claim on this page was checked against a standard AgelessRx set for itself.